FDC Ltd
Company Profile
Business description
FDC Ltd is principally engaged in the business of manufacturing and trading pharmaceutical products. It has its presence in numerous therapeutic segments including anti-infectives, gastrointestinal treatments, ophthalmics, vitamins, minerals, dietary supplements, cardiovascular solutions, anti-diabetics, and others. The company's different pharmaceutical products are marketed through brands such as Electral, Enerzal, Zifi, Zocon, Vitcofol, Otek Ac Neo, Amodep AT, Simyl MCT Oil, and many others. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and other regions.
Contact
B-8, M.I.D.C. Industrial Estate
Waluj
Chhatrapati Sambhaji Nagar (Aurangabad)MH431136
INDT: +91 2402554407
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
6,975
Stocks News & Analysis
stocks
After earnings, is Microsoft a buy, a sell, or fairly valued?
stocks
Albemarle earnings: Shares rally on strong profit growth well above consensus estimates
stocks
Ahead of IPOs, AI giants keep making circular deals. Here’s why that’s a risk - Clone
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,980.50 | 31.60 | -0.35% |
| CAC 40 | 8,147.14 | 54.94 | -0.67% |
| DAX 40 | 24,458.33 | 205.28 | -0.83% |
| Dow JONES (US) | 49,743.20 | 146.23 | 0.29% |
| FTSE 100 | 10,273.49 | 3.46 | -0.03% |
| HKSE | 26,393.71 | 232.57 | -0.87% |
| NASDAQ | 26,023.69 | 217.49 | 0.84% |
| Nikkei 225 | 62,713.65 | 120.19 | -0.19% |
| NZX 50 Index | 13,175.13 | 95.48 | -0.72% |
| S&P 500 | 7,376.07 | 38.96 | 0.53% |
| S&P/ASX 200 | 8,744.40 | 36.40 | -0.41% |
| SSE Composite Index | 4,179.95 | 0.14 | -0.00% |